Regulus, UCSD Partner on miRNA for Angiogenic Diseases | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Regulus Therapeutics today announced it is collaborating with researchers at the University of California, San Diego School of Medicine to develop treatments for angiogenic disease using microRNA therapeutics.

The collaboration combines Regulus' miRNA platform with UCSD's expertise in animal models of angiogenesis. The collaboration recently received a UC Discovery Grant that promotes work between the university's researchers and industry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.